BioNTech’s Bold Journey: From Vaccine Glory to Cancer Therapy Frontier
BioNTech reported a decrease in 2024 profits to €1.08 per share, down from €1.90, yet still surpassing market expectations of €0.407. Revenues fell to €1.19 billion, outperforming forecasts of €1.093…